GlassScriptPhysician profile
Clan H Hahn
NPI 1023043189
$13,444.44
in general payments reported to CMS, 2019-2025
51 companies · $6,244 in 2025
The $6,244 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.38 · 2022: $628 · 2023: $2,336 · 2024: $4,216 · 2025: $6,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $499 · Education: $69.00 · Entertainment: $13.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,214.48 |
| Long Term Medical Supply Or Device Loan | $498.50 |
| Education | $69.00 |
| Entertainment | $13.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,722.43 | 2022-2025 | Opdivo, Opdualag, Reblozyl |
| Novartis Pharmaceuticals Corporation | $1,116.66 | 2023-2025 | |
| Pfizer INC. | $999.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $835.58 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $792.19 | 2023-2025 | Reblozyl, Pomalyst, Breyanzi |
| Regeneron Healthcare Solutions, INC. | $577.10 | 2023-2025 | Libtayo |
| Exelixis INC. | $571.11 | 2023-2025 | Cabometyx |
| Genzyme Corporation | $554.05 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $551.37 | 2022-2025 | Tagrisso, Lynparza, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $425.08 | 2023-2025 | |
| Secura Bio, INC. | $418.35 | 2023-2025 | Copiktra |
| Janssen Biotech, INC. | $392.96 | 2022-2025 | Rybrevant, Balversa, Erleada |
| Gilead Sciences, INC. | $377.19 | 2023-2025 | Trodelvy |
| Incyte Corporation | $375.44 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Adaptive Biotechnologies Corporation | $289.59 | 2024-2025 | Clonoseq |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $281.92 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.14 | 2024-2025 | Gilotrif |
| Eisai INC. | $229.24 | 2024-2025 | |
| Caris Mpi, INC. | $217.50 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $188.21 | 2025 | Orserdu |
| Genentech USA, INC. | $187.12 | 2023-2025 | Venclexta, Tecentriq, Rozlytrek |
| Pharmaessentia USA Corporation | $177.72 | 2023-2025 | Besremi |
| Daiichi Sankyo INC. | $171.64 | 2024-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $144.11 | 2023-2025 | Iclusig, Fruzaqla |
| Jazz Pharmaceuticals INC. | $134.96 | 2024-2025 | |
| Glaxosmithkline, LLC. | $121.67 | 2022-2025 | Jemperli, Zejula, Blenrep |
| Amgen INC. | $115.75 | 2022-2023 | Lumakras |
| Emd Serono, INC. | $112.01 | 2023-2024 | Bavencio |
| Mirati Therapeutics, INC. | $111.60 | 2023-2024 | Krazati |
| Abbvie INC. | $97.63 | 2024-2025 | |
| Puma Biotechnology, INC. | $89.08 | 2025 | |
| Sanofi-Aventis U.S. LLC | $69.00 | 2025 | |
| Immunogen, INC. | $67.64 | 2023-2024 | Elahere, Elahere |
| Azurity Pharmaceuticals, INC. | $60.83 | 2024-2025 | Danziten, Vivimusta |
| Aveo Pharmaceuticals, INC. | $58.87 | 2025 | |
| Taiho Oncology, INC. | $58.41 | 2025 | |
| Astellas Pharma US INC | $53.83 | 2025 | Padcev |
| Beigene USA, INC. | $50.30 | 2023-2024 | Brukinsa |
| Legend Biotech USA INC. | $47.10 | 2025 | Carvykti |
| Springworks Therapeutics, INC. | $40.63 | 2024 | Ogsiveo |
| Myriad Genetic Laboratories, INC. | $35.35 | 2024 | Myrisk |
| Boston Scientific Corporation | $34.82 | 2023-2024 | Wavewriter Alpha Prime 16, Lux-Dx Insertable Cardiac Monitor |
| Adc Therapeutics America, INC. | $33.46 | 2025 | |
| Sobi, INC | $31.36 | 2025 | |
| Tempus Ai, INC | $30.83 | 2025 | Xt Cdx |
| Deciphera Pharmaceuticals INC. | $30.19 | 2023 | Qinlock |
| Nuvation Bio INC. | $28.35 | 2025 | Ibtrozi |
| Alnylam Pharmaceuticals INC. | $27.78 | 2022 | |
| Iovance Biotherapeutics, INC. | $26.47 | 2025 | Amtagvi |
| Blueprint Medicines Corporation | $22.91 | 2024 | Ayvakit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.49 | 2025 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clan Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.